The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist
given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial
fibrillation) and a recent heart attack or a recent procedure to open up a blood vessel in
the heart. All patients would also be taking a class of medicines called P2Y12 inhibitors
(such as clopidogrel/Plavix) and be treated for up to 6 months. The primary focus will be a
comparison of the bleeding risk of Apixaban, with or without aspirin, versus a Vitamin K
antagonist, such as warfarin, with or without aspirin.